<DOC>
	<DOCNO>NCT02784834</DOCNO>
	<brief_summary>The purpose study investigate safety investigational drug call dimethylfumarate ( DMF ) . DMF type drug call immunomodulatory drug . This drug approve United States ( U.S. ) Food Drug Administration ( FDA ) treatment patient multiple sclerosis . Although evidence test laboratory animal DMF decrease number CLL cell , know work human CLL . This drug give human CLL first time study . Therefore , goal study see DMF safe tolerable study participant . Participants evaluate find effect ( good bad ) DMF body see long drug stay body .</brief_summary>
	<brief_title>Dimethylfumarate ( DMF ) Relapsed/Refractory CLL/SLL</brief_title>
	<detailed_description>This phase I clinical trial evaluate safety , tolerability , maximum tolerate dose DMF patient chronic lymphocytic leukemia . Patients relapsed/refractory CLL amenable available therapy eligible . This patient population need novel therapy , particularly progressing , intolerant , unable receive oral tyrosine kinase inhibitor ( ie ibrutinib , idelalisib ) . For Dose Level 1 , DMF ( Tecfidera formulation ) administer dose 120 mg PO BID ( approximately 12 hour apart ) 2 x 28 day cycle . For Dose Level 2 , DMF administer currently use dose patient multiple sclerosis : standard FDA approve dose 120 mg PO BID ( approximately 12 hour apart ) 1 week , escalate assign dose ( 240mg PO BID remainder 2 x 28 day cycle . The 1 week lead-in 120 mg assist toleration initial side effect per standard prescribe information . For Dose Level 3 , DMF administer currently use dose patient multiple sclerosis : 120 mg PO BID 1 week , escalate dose 360mg PO BID remainder 2 x 28 day cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Clinical phenotypic verification B cell CLL/ SLL/ MBL measurable disease . Relapsed refractory disease Previously treat least 1 regimen CLL/SLL Not appropriate amenable approve therapy . All patient must progress Bcell receptor target kinase inhibitor ( eg : ibrutinib , idelalisib , ACP196 , CC292 ) , unless relative contraindication ( eg : history recent bleeding , history atrial fibrillation , unacceptable high outofpocket cost despite patient assistance program ) . Patients Del ( 17p ) CLL must progress BCL2 inhibitor therapy ( eg : venetoclax ) , unless relative contraindication ( eg : Creatinine clearance &lt; 50ml/min , unable monitor TLS due living remotely medical center , unacceptably high outofpocket cost ) . Patients must receive CD20directed monoclonal antibody ( eg : obinutuzumab , ofatumumab , rituximab ) , unless relative contraindication ( eg : history hepatitis virus infection ) . Has recover toxic effect prior therapy clinical baseline . Women childbearing potential must agree become pregnant duration study . Both men woman must agree use barrier method contraception duration study 8 week final dose . Subjects must least one follow indication treatment : Symptomatic progressive splenomegaly ; Symptomatic lymph node , nodal cluster , progressive lymphadenopathy ; Progressive anemia ; Progressive thrombocytopenia ; Weight loss &gt; 10 % body weight precede 6 month period ; Fatigue attributable CLL ; Fever night sweat &gt; 2 week without evidence infection ; Progressive lymphocytosis increase &gt; 50 % 2month period anticipate doubling time le 12 month . ECOG performance status 02 . Adequate hematologic function Adequate renal function Adequate hepatic function Pregnant breastfeed woman enter study . Patients currently receive another investigational agent exclude . Patients chemotherapy ( e.g. , purine analogue , alkylating agent ) , radiation therapy , participation investigational drug treatment within 4 week initiation DMF time study . Patients prior ( within 8 week initiation DMF ) concurrent antibody therapy direct CLL ( i.e . Rituxan Campath ) Patients tyrosine kinase inhibitor therapy ( eg : ibrutinib idelalisib ) within 7 half life ( 28 day , ever short ) initiation DMF . Current infection require parenteral antibiotic . Active malignancy within previous 2 year ( completely resect nonmelanoma skin cancer carcinoma situ ) . Insufficient recovery surgicalrelated trauma wound healing . Impaired cardiac function include follow : Myocardial infarction within 6 month start study drug ; Other clinically significant heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>cancer</keyword>
	<keyword>DMF</keyword>
	<keyword>SLL</keyword>
	<keyword>dimethylfumarate</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>